We de-identify protected health information using HIPAA's Safe Harbor and Expert Determination methods — structured data pipelines, clinical text NLP, limited dataset creation, and re-identification risk validation so your analytics and AI programs can access the data they need.
Talk to our team about your dataset and analytics use case. We reply within 24 hours.
Healthcare data is among the most valuable raw material for clinical research, analytics, and AI development. De-identification removes the elements that link data to individual patients — creating datasets that retain clinical value while exiting HIPAA's privacy and security requirements entirely.
Removal of all eighteen HIPAA-specified identifier categories — names, geographic data smaller than a state, dates beyond year, phone numbers, SSNs, medical record numbers, IP addresses, device identifiers, biometric data, and more. Ages over 89 are aggregated. After removal, the organization must have no actual knowledge the remaining data could identify an individual.
A qualified statistical or scientific expert applies generally accepted principles to establish that re-identification risk is very small. More flexible than Safe Harbor — some identifiers may be retained if risk analysis supports it — but requires documented methodology and qualified expertise. Expert analysis and documentation are essential to a defensible determination.
Systematic transformation of identifier fields in relational databases, HL7, and FHIR data — including generalization of exact dates to year-only, ages to ranges, and suppression of rare attribute combinations that function as de facto identifiers. Automated pipelines process large record volumes consistently and reproducibly, with documented provenance.
Natural language processing techniques that recognize and redact or replace named entities in clinical notes, radiology reports, and discharge summaries — patient names, physician names, locations, dates, and other identifiers embedded in unstructured narrative text. The same identifier appears in many forms across clinical text, requiring trained NLP models.
HIPAA's limited dataset framework removes direct identifiers while retaining certain indirect identifiers such as city, state, zip code, and dates — usable for research, public health, and healthcare operations under a Data Use Agreement. A practical middle ground between fully identified PHI and fully de-identified data for analytics use cases.
Even after obvious identifiers are removed, combinations of demographic and clinical attributes can re-identify individuals in small populations or unusual clinical profiles. Re-identification risk assessment evaluates how remaining data could be combined with other available information — and guides suppression, generalization, or noise-addition decisions.
A structured process from data inventory to risk validation — each step with specific technical and compliance deliverables that determine whether a de-identified dataset can be used for analytics and AI development without HIPAA privacy constraints.
HIPAA's privacy constraints on identifiable PHI significantly limit how healthcare data can be used for model development and analytics. De-identification is the mechanism that unlocks that data — click through to see what changes.
Book a De-Identification ConsultationUnder 45 CFR 164.514(b), Safe Harbor de-identification requires removal of eighteen specific identifier categories. After removal, the organization must have no actual knowledge the remaining information could identify any individual.
Direct identifiers that link data to a specific named individual.
Geographic and contact information that can locate or reach an individual.
Temporal data requires special handling — dates beyond year and ages over 89 are identifying.
Physical and technical identifiers unique to devices or biological characteristics.
The Expert Determination method allows retention of some identifiers when risk analysis supports it.
Limited datasets remove direct identifiers but may retain indirect ones — usable under a Data Use Agreement.
NLP models, structured data pipelines, and risk validation tooling — selected to match the data formats, volumes, and compliance posture of clinical datasets used in healthcare AI and analytics.
S
spaCy NLP
A
AWS Comprehend Medical
A
Azure Health NLP
G
Google Healthcare API
B
BERT Clinical Models
F
FHIR De-Identification
H
HL7 Transformation
S
SQL Masking Pipelines
A
Apache Spark
D
dbt Transforms
K
k-Anonymity Analysis
L
l-Diversity
T
t-Closeness
A
ARX Framework
D
Differential Privacy
A
AWS HealthLake
A
Azure Health Data
G
Google HCAPI
4
45 CFR 164.514
D
Data Use Agreements
Safe Harbor or Expert Determination, structured pipelines or clinical NLP, limited datasets or fully de-identified — we build the de-identification framework that matches your data formats, your analytics use case, and your compliance posture. Book a consultation and we will map the right approach for your dataset.
Book a De-Identification Consultation
100 Fastest Growth Companies
Global Spring Winner
Top App Development Company
AWS Partner Network
Google Cloud Partner
Highly Rated on Trustpilot
Verified Agency
Top App Development Company
ASSOCHAM Member
De-identified data produced under HIPAA's Safe Harbor or Expert Determination methods is treated as non-PHI for legal purposes, but this does not mean it is impossible in practice to re-identify individuals from such data. Research has demonstrated that combining de-identified health data with other publicly available data sources can sometimes re-identify individuals, particularly those with unusual demographic characteristics or rare conditions. Organizations working with de-identified data should implement contractual and technical controls to prevent re-identification attempts and should treat the data with appropriate care even in the absence of HIPAA's legal requirements.
A Data Use Agreement is a contractual arrangement required by HIPAA when a covered entity shares a limited dataset with another party for research, public health, or healthcare operations purposes. The limited dataset recipient must agree to use the data only for the purposes specified in the agreement, to not attempt to identify the individuals in the dataset, and to implement safeguards to prevent unauthorized use or disclosure. Data Use Agreements are simpler to execute than full HIPAA authorizations but are still legally binding agreements with specific required provisions.
Safe Harbor requires removing all eighteen specified identifier categories from the dataset — it is straightforward to audit and implement but removes more data than may be necessary. Expert Determination requires a qualified statistical or scientific expert to apply accepted principles and document that re-identification risk is very small. Expert Determination is more flexible because it allows retention of some identifiers when risk analysis supports it, but it requires qualified expertise to implement and the expert's analysis must be documented. For AI training datasets where richer clinical data improves model performance, Expert Determination often provides better outcomes than Safe Harbor's blanket removals.
Yes. Once data has been appropriately de-identified under 45 CFR 164.514 — through Safe Harbor or Expert Determination — it is no longer PHI and is not subject to HIPAA's Privacy and Security Rules. It can be shared with AI vendors, used in cloud model training environments, and incorporated into product development workflows without the Business Associate Agreement requirements that apply to identified PHI. However, organizations should implement contractual prohibitions on re-identification attempts and should evaluate the AI vendor's data handling practices independent of HIPAA requirements.
